Marathon Oil is a restructuring story and is cheap compared to fellow North American E&P players, said Thomas Forester, portfolio manager for the Forester Value Fund. Forester added that Marathon is still immensely profitable even with oil prices moderating. Forester is also bullish on Amgen, saying the biotech powerhouse has a full pipeline and is under less pressure from biologic competition than Wall Street originally predicted. Finally, Forester is positive on J.C. Penney, stating that the retailer has turned itself around and it’s stock does not have to move very far to become a tremendously profitable investment.